Mahraz Parvand

Ophthalmic drug development has historically yielded relatively few novel molecular entities (NME), with most Food and Drug Administration (FDA) approvals reflecting reformulations or incremental therapeutic advances rather than biologic or pathway-expanding innovation [1, 2]. However, recent advances in molecular targeting, biologic therapies, and treatments for rare ocular diseases suggest that patterns of innovation in ophthalmology may be changing.

E.T. has received honorarium for speaking engagements from Amicus Therapeutics. T.S. has received honorarium for speaking engagements and advisory boards from KYE pharmaceuticals, Sanofi, Amgen, Pfizer, HLS pharmaceuticals, Novartis, BI-Lilly and Novo Nordisk. The other authors do not have any financial disclosures. This work was supported through the 2022 BC Women's Hospital Women's Health Research Institute Catalyst Grant and support from the VGH Foundation.